CD4 and myeloid sarcoma: Previously, our group showed that they suppress the proliferation of a CD4+ T-cell line derived from a MS patient, stimulate T-cell responses in peripheral blood monocytes from MS patients inducing Th2 responses when used to immunize mice, show good binding to human HLA-DR4, and show improved stability to proteolysis over linear analogues [24,25,26,27].